Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited ( (AU:FRE) ) just unveiled an update.
Firebrick Pharma Limited has requested an immediate trading halt in its securities on the ASX while it prepares an announcement regarding a proposed placement. Trading in FRE shares will remain halted until the placement announcement is released or until normal trading resumes on Tuesday, 31 March 2026, unless the exchange decides otherwise.
The company stated it is not aware of any reason the trading halt should be refused and confirmed there is no additional information necessary to inform the market about the halt. The pending placement announcement is likely to relate to capital raising activities, which could affect Firebrick Pharma’s funding position and be material for existing and prospective shareholders.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australia-based pharmaceutical company listed on the ASX under the ticker FRE. The company operates in the healthcare sector and its activities focus on developing and commercialising pharmaceutical products, serving investors and stakeholders in the Australian capital markets.
Average Trading Volume: 62,074
Technical Sentiment Signal: Sell
Current Market Cap: A$13.63M
See more data about FRE stock on TipRanks’ Stock Analysis page.